Medicine and Dentistry
Radiation Therapy
100%
Malignant Neoplasm
98%
Overall Survival
96%
Chemoradiotherapy
60%
Neoplasm
56%
Esophageal Cancer
49%
Odds Ratio
48%
Hepatocellular Carcinoma
47%
Rectum Cancer
47%
Disease
43%
Squamous Cell Carcinoma
39%
Radiation Therapy
37%
Colorectal Cancer
36%
External Beam Radiotherapy
32%
Adjuvant Chemotherapy
31%
Hazard Ratio
28%
Pancreas Cancer
28%
Prevalence
27%
Logistic Regression Analysis
26%
Oncology
24%
Colon Cancer
23%
Prostate Cancer
23%
Symptomatic Treatment
17%
Radiation Oncology
16%
Racial Disparity
16%
Cancer
16%
Adenocarcinoma
15%
Cancer Diagnosis
15%
Meta-Analysis
14%
Anal Cancer
14%
Surgery
14%
Electronic Cigarette
14%
Quality of Life
13%
Stereotactic Body Radiation Therapy
13%
Squamous Cell
13%
Recurrent Disease
13%
Proportional Hazards Model
13%
Proton Therapy
13%
Pancreas Adenocarcinoma
12%
Recurrence Free Survival
12%
High Risk Population
12%
Colonoscopy
11%
Positron Emission Tomography
11%
Progression Free Survival
11%
Contouring
11%
Ethnic Group
9%
Randomized Controlled Trial
9%
Health Care Cost
9%
Primary Tumor
9%
Time to Treatment
9%
Keyphrases
Radiation Therapy
47%
United States
43%
Overall Survival
37%
Colorectal Cancer
30%
Adjusted Odds Ratio
30%
Confidence Interval
28%
Chemotherapy
26%
Older Adults
23%
Ablative Radiation Therapy
22%
Non-Hispanic White
20%
Radiotherapy
18%
Clinical Outcomes
17%
Hazard Ratio
16%
Hepatocellular Carcinoma
16%
Cancer Diagnosis
16%
Age 50
16%
Combined Modality Therapy
15%
Esophageal Cancer
15%
Adjuvant Chemotherapy
15%
Metastatic Colorectal Cancer (mCRC)
15%
Survivors
14%
Pancreatic Cancer
14%
Stereotactic Ablative Radiotherapy
14%
Cancer Survivors
14%
Population-based Study
14%
Anal Squamous Cell Carcinoma
14%
Radiation Oncology
14%
Treatment Parameters
14%
Expert Consensus
14%
Multivariable
13%
Tumor
13%
Locally Recurrent
12%
Comorbidity
12%
Immune Checkpoint Inhibitors
11%
Locally Advanced
10%
Multivariable Logistic Regression
10%
Old Age
10%
Prognostic Value
10%
Adenocarcinoma of the Esophagogastric Junction
10%
Oncological Outcomes
10%
Oncologists
9%
Age Groups
9%
Locally Advanced Rectal Cancer
9%
Recurrence-free Survival
8%
Young-onset
8%
Ethnic Groups
8%
Cancer Inpatients
8%
Osteosarcoma
8%
Dose Escalation
8%
Young Age
8%